Bloodline

Young people with bleeding disorders score in the David Beckham Football Academy, Greenwich
InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment Of Paroxysmal Nocturnal Hemoglobinuria (PNH)
FDA Clears Osmetech's Warfarin Sensitivity Test And New ESensor® XT-8 Platform

1. The Crookston Collection (Slide Images)    (Category: References)
2. HEMEX Laboratories    (Category: Treatment and Research Centers)
3. BMTSAA    (Category: Organizations)
4. Non-Hodgkin's Lymphoma Cyberfamily    (Category: Patient Information)
5. WFCC-MIRCEN World Data Centre for Microorganisms (WDCM)    (Category: References)

Bloodline Reviews, Volume 5, Issue 3

Article Index
Bloodline Reviews, Volume 5, Issue 3
CME Information
Presentations

Page 3 of 3

mds_small_banner

	Recent Advances in the Treatment of Patients with Myelodysplasia Daniel J. DeAngelo, MD, PhD Assistant Professor of Medicine Dana-Farber Cancer Institute Boston, Massachusetts View Presentation
	Minimally Symptomatic Myelodysplastic Syndrome:Initial Therapeutic Considerations Larry D. Cripe, MD Dana-Farber Cancer Institute Indiana University Cancer Center Indianapolis, Indiana View Presentation
	Intermediate-Risk MDS Unresponsive to Erythropoietin:Using IPSS to Design Successful Treatment Outcomes Lewis R. Silverman, MD Assistant Professor of Medicine Mount Sinai School of Medicine New York, New York View Presentation
	High-Risk MDS:The Role of Induction Chemotherapy and Transplantation John M. McCarty, MD Medical Director Bone Marrow Transplantation Program Massey Cancer Center at VCU Medical Center Richmond, Virginia View Presentation
	Myelodysplastic Syndrome with Challenging Cytogenetics Mikkael A. Sekeres, MD Assistant Professor of Medicine Cleveland Clinic Cleveland, Ohio View Presentation
	Download a PDF of the Program Post-Test and Activity Evaluation/Request for Credit Form